Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지

Cytotoxicities of Tumor-specific T Lymphocytes Primed by Glioma Apoptotic Body - or Glioma Cell Lysate-pulsed Dendritic Cells

  • Kim, Jong-Tae (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea) ;
  • Chung, Dong-Sup (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kwak, Seung-Won (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea) ;
  • Han, Young-Min (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Young-Sup (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Moon-Chan (Department of Neurosurgery, Our Lady of Mercy Hospital, College of Medicine, The Catholic University of Korea)
  • Published : 2005.08.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The choice of tumor antigen for dendritic cell[DC]-loading has still been an unresolved problem in the DC-based vaccine strategies against malignant gliomas that has not been found well-characterized tumor specific antigens. In this study, we compare tumor-specific T cell response induced by glioma apoptotic body[GAB]-pulsed DCs to response induced by glioma cell lysate-pulsed ones quantitatively. Methods : DCs generated in the presence of granulocyte macrophage-colony stimulating factor and interleukin[IL]-4 from peripheral blood mononuclear cells[PBMCs] of HLA-A2 positive healthy donors were cultured. Each GABs and glioma cell lysate generated from HLA-A2 positive T98G glioblastoma cells were co-incubated with DCs. $CD8^+$ T lymphocytes isolated from PBMCs of same donors were cultured in media containing IL-2 and either stimulated by GAB- or lysate-pulsed DCs three times at a weekly interval. The interferon[IFN]-${\gamma}$ concentrations of each cell culture supernate were measured by enzyme immunoassay technique. Cytolytic activity of the generated cytotoxic $CD8^+$ T cells either stimulated with GAB- or lysate-pulsed DCs was determined by a standard 4-h $^{51}Cr$-release assay. Results : IFN-${\gamma}$ production and cytolytic activity of effector T cells stimulated by GAB-pulsed DCs were significantly higher than those of T cells stimulated by lysate-pulsed ones. Conclusion : These results indicate the choice of antigen is a critical determinant in the induction of antitumor immunity against malignant glioma. Antigen preparations from GABs represent a promising alternative to glioma cell lysate in DC-based glioma vaccine strategies.

Keywords

References

  1. Albert ML, Sauter B, Bhardwaj N : Dendritic cells acquire antigen from apoptotic cells and induce class I-resrricted CTLs. Nature 392 : 86-89, 1998 https://doi.org/10.1038/32183
  2. Amoscato AA, Prenovitz DA, Lotze MT : Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161 : 4023-4032, 1998
  3. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al : Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 : 6451-6458, 2001
  4. Banchereau , Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998 https://doi.org/10.1038/32588
  5. Feng H, Zeng Y, Whitesell L, Katsanis E : Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 97 : 3505-3512, 2001 https://doi.org/10.1182/blood.V97.11.3505
  6. Hoffmann TK, Meidenbauer N, Dworachi G, Kanaya H, Whiteside TL : Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60 : 3542-3549, 2000
  7. Hunter CA, Reiner SL : Cytokines and T cells in host defense. Curr Opin Immunol 12: 413-418, 2000 https://doi.org/10.1016/S0952-7915(00)00110-2
  8. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al : Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188: 2163-2173, 1998 https://doi.org/10.1084/jem.188.11.2163
  9. Jenne L, Arrighi JF, Jonuleir H, Saurat JH, Hauser C : Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 60 : 4446-4452, 2000
  10. Kim IS, Kim JT, Cho HI, Park YS, Kim MC, Chung DS : Induction of cellular immune response by dendritic cells pulsed with glioma apoptotic bodies. J Korean Neurosurg Soc 34 : 360-365, 2003
  11. Kurts C, Miller JFAP, Subramanium R, Carbone FR, Heath WR : Major hisrocompatibility complex class I-restricted cross-presentation is biased towards hight dose antigens and those released during cellular destruction. J Exp Med 188 : 409-414, 1998 https://doi.org/10.1084/jem.188.2.409
  12. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, et al : A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-I)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5: 1331-1228, 1999
  13. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al. : Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 : 1115-1124, 1999 https://doi.org/10.3171/jns.1999.90.6.1115
  14. Parajuli P, Mathupala S, Sloan AE : Systemic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas : in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55 : 1194-1204, 2004 https://doi.org/10.1227/01.NEU.0000141082.20865.48
  15. Rubin J, Lotze M : Adoptivecellular immunotherapy ofcancer in Mitchel M (ed) : Biological approaches to cancer treatment: biomodulation, New York, McGraw-Hill, Inc., 1993, pp379-410
  16. Sallusto F, Nicolo C, De Maria R, Corinti S, Testi R: Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med 184 : 2411-2416, 1996 https://doi.org/10.1084/jem.184.6.2411
  17. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Robe J, et al : Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62: 2347-2352, 2002
  18. Steinman RM : The dendritic cell system and its role in immunogenicity [Review]. Annu Rev Immunol 9: 271-296,1991 https://doi.org/10.1146/annurev.iy.09.040191.001415
  19. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, er al : Vaccinationwith mage-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cyrotoxic T cells and induces regression of some metastases in advanced srage IV melanoma. J Exp Med 190: 1669-1678, 1999 https://doi.org/10.1084/jem.190.11.1669
  20. Tjoa BA : Evaluation ofphase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36 : 39-44, 1998 https://doi.org/10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6
  21. Todryk S, Melcher AA, Hardwick N, Linardkis E, Bateman A, Colombo MP, et al : Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163: 1398-1408, 1999
  22. Yoshida S, Morii K, Watanabe M, Saito T, Yamamoto K, Tanaka R: The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors. Cancer Immunol Immunother 50: 321-327, 2001 https://doi.org/10.1007/s002620100201
  23. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al : Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842-847, 2001